Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

Thumbnail
View/Open
Accepted version (281.6Kb)
Date
2016-05
ICR Author
Oyen, Willem
Author
Muselaers, CHJ
Boers-Sonderen, MJ
van Oostenbrugge, TJ
Boerman, OC
Desar, IME
Stillebroer, AB
Mulder, SF
van Herpen, CML
Langenhuijsen, JF
Oosterwijk, E
Oyen, WJG
Mulders, PFA
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Unlabelled Despite advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), there is still an unmet need in the treatment of this disease. A phase 2 radioimmunotherapy (RIT) trial with lutetium 177 ((177)Lu)-girentuximab was initiated to evaluate the efficacy of this approach. In this nonrandomized single-arm trial, patients with progressive metastatic ccRCC who met the inclusion criteria received 2405 MBq/m(2) of (177)Lu-girentuximab intravenously. In the absence of persistent toxicity and progressive disease, patients were eligible for retreatment after 3 mo with 75% of the previous activity dose. A total of 14 patients were included. After the first therapeutic infusion, eight patients (57%) had stable disease (SD) and one (7%) had a partial regression. The treatment was generally well tolerated but resulted in grade 3-4 myelotoxicity in most patients. After the second cycle, continued SD was observed in five of six patients, but none were eligible for retreatment due to prolonged thrombocytopenia. In conclusion, RIT with (177)Lu-girentuximab resulted in disease stabilization in 9 of 14 patients with progressive metastatic ccRCC, but myelotoxicity prevented retreatment in some patients.Patient summary We investigated the efficacy of lutetium 177-girentuximab radioimmunotherapy in patients with metastatic kidney cancer. The treatment resulted in disease stabilization in 9 of 14 patients. The main toxicity was prolonged low blood cell counts.Trial registration ClinicalTrials.gov identifier: NCT02002312 (https://clinicaltrials.gov/ct2/show/NCT02002312).
URI
https://repository.icr.ac.uk/handle/internal/554
DOI
https://doi.org/10.1016/j.eururo.2015.11.033
Collections
  • Radiotherapy and Imaging
Subject
Humans
Carcinoma, Renal Cell
Kidney Neoplasms
Thrombocytopenia
Neutropenia
Lutetium
Radioisotopes
Antibodies, Monoclonal
Disease-Free Survival
Radioimmunotherapy
Retreatment
Non-Randomized Controlled Trials as Topic
Carbonic Anhydrase IX
Antineoplastic Agents, Immunological
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2015-11-27
License start date
2016-05
Citation
European urology, 2016, 69 (5), pp. 767 - 770

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.